Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: Effects on hemodynamics and catecholamine metabolism in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 4, 1996, Pages 450-457

  Illi, Ari ^a   Sundberg, Stig ^b   Ojala Karlsson, Pirjo ^b   Scheinin, Mika ^b   Gordin, Ariel ^b  

^a ORION CORPORATION   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ADRENALIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CATECHOLAMINE; ENTACAPONE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PLACEBO;

ADULT; ARTICLE; CATECHOLAMINE METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ENZYME INHIBITION; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; BENZAMIDES; CATECHOL O-METHYLTRANSFERASE; CATECHOLAMINES; CATECHOLS; CROSS-OVER STUDIES; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; EXERCISE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; REFERENCE VALUES; REST;

EID: 0029881150     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90115-0     Document Type: Article

References (24)

1. Bäckström R, Honkanen E, Pippuri A, et al. Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors. J Med Chem 1989;32: 841-6.
2. Nissinen E, Lindén IB, Schultz E, Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 1992; 346:262-6.
3. Keränen T, Gordin A, Harjola VP, et al. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993;16:145-56.
4. Myllylä VV, Sotaniemi KA, Illi A, Keränen T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease Eur J Clin Pharmacol 1993;45:419-23.
5. Merello M, Lees A, Webster R, Bovingdon M, Gordin A. The effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute L-dopa administration in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:186-189.
6. Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and L-dopa metabolism in parkinsonian patients. Neurology 1994;44:77-80.
7. Ruottinen H, Rinne UK. Effect of one month's treatment with peripherally acting COMT inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol [In press].
8. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-9.
9. Haefely W, Burkard WP, Cesura A, et al. Pharmacology of moclobemide. Clin Neuropharmacol 1993; 16(suppl 2):S8-18.
10. Törnwall M, Männistö P. Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission. Pharmacol Toxicol 1991;69:64-70.
11. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992;149:443-54.
12. Karasu TB, Docherty JP, Gelenberg A. Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993;150(suppl 4):1-26.
13. Ruggieri S, Stocchi F, Bramante L, et al. MAO-A inhibitor (moclobemide) has a symptomatic effect in Parkinson's disease [Abstract]. Mov Disord 1994; 9(suppl 1):72.
14. Dingemanse J. An update of recent moclobemide interaction data. Int Clin Psychopharmacol 1993;7:167-80.
15. Scheinin M, Chang WH, Jimerson DC, Linnoila M. Measurement of 3-methoxy-4-hydroxyphenylglycol in human plasma with high-performance liquid chromatography using electrochemical detection. Anal Biochem 1983;132:165-70.
16. 2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers. Life Sci 1991;49:75-84.
17. Ojala-Karlsson P, Scheinin M. Improved high-performance liquid chromatographic method for the routine determination of unconjugated 3-methoxy-4-hydroxyphenylenglycol in human plasma using solid-phase extraction and electrochemical detection. J Chromatogr 1991;565:131-9.
18. Sundberg S, Scheinin M, Ojala-Karlsson P, Akkila J, Gordin A. The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition. Eur J Clin Pharmacol 1993;44:287-90.
19. Karlsson M, Wikberg T. Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. J Pharm Biomed Anal 1992;10:593-600.
20. Jones B, Kenward M. Design and analysis of crossover trials. London: Chapman and Hall, 1989.
21. Gasic S, Korn A, Eichler HG, Oberhummer I, Zapotoczky HG. Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients. Eur J Clin Pharmacol 1983;25:173-7.
22. Koulu M, Scheinin M, Kaarttinen A, et al. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 1989;27:243-55.
23. Sundberg S, Scheinin M, Illi A, Akkila J, Gordin A, Keränen T. The effects of the COMT inhibitor entacapone (OR-611) on hemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol 1993;36:451-6.
24. Illi A, Sundberg S, Koulu M, Scheinin M, Heinävaara S, Gordin A. COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharmacol Ther 1994; 32:582-8.